EAACI Congress 2025
BackJMA Poster session 08 - JMA Poster Session 8: ENT/Asthma/Environmental Allergy/Ocupational Allergy
Friday 13 Jun, 16:30 PM -
18:00 PM Glasgow, United Kingdom
Poster Zone
JMA
16:30
5-Year Metal Patch Testing Analysis of a Portuguese Immunology an Allergology Center: Allergen relevance and Cluster identification
16:30
Balancing Green Initiatives with Public Health: A Framework for Allergy-Friendly Urban Planning
16:30
Characterization of Juniperus oxycedrus pollen extract and identification of putative allergens
16:30
Climate Change and Asthma: Medical Student Knowledge and Perception Questionnaire
16:30
Dissecting the molecular mechanisms underlying TSLP-driven non-type 2 inflammatory responses in severe asthma
16:30
Exploring association between lung function, asthma and epigenetic predisposition to obesity
16:30
ICS use trajectories in severe asthma patients on benralizumab: real-life data from 3-years follow-up
16:30
IgE cross-reactivity between grass species in the presence of Japanese cedar pollen sensitization
16:30
Inhibition of the Interleukin Cytokines using novel Peptide Inhibitors for Allergy and Asthma Treatment
16:30
Nasal transcriptomics as a biomarker for ICS/LABA treatment in paediatric asthma in the PUFFIN study
16:30
Occupational Asthma due to Inhaled Mare's Milk Exposure and Anaphylaxis Associated with Plantago ovata
16:30
Oscillometry and spirometry derived ratios to assess small airways dysfunction in severe asthma patients taking tezepelumab
16:30
Systemic characteristic of 15-LOX and 5-LOX oxo-metabolites in older patients with aspirin exacerbated respiratory disease
16:30
The Impact of Obesity in Asthma and Small Airway Dysfunction: Prevalence, Clinical characteristics, and Predictors
16:30
The Respiratory Microbiota and Serum Metabolomics Characteristics in Different Endotypes of Asthma
16:30
The Role of Inflammatory Parameters in Predicting Allergy in Childhood Asthma
16:30
What are our children breathing? Tracking exposure to air pollution during a school day
16:30
Worse airflow obstruction but not type 2 biomarkers identifies super-responders to tezepelumab in a real life clinic setting
